Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349791 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
A Phase 3 study of Hypoactive Sexual Desire Disorder (HSDD), sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 549
- Enrollment target
- 3
- Study locations
NCT00349791: Completed Phase 3 study of Hypoactive Sexual Desire Disorder (HSDD), sponsored by Warner Chilcott.
NCT00349791 is a Phase 3 study of Hypoactive Sexual Desire Disorder (HSDD) that has completed, run by Warner Chilcott. The registered enrollment target is 549 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00349791, a Phase 3 study of Hypoactive Sexual Desire Disorder (HSDD), has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 549 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
Conditions Studied
Interventions
- DRUG Placebo patch
- DRUG Testosterone Transdermal System
Study Locations (3)
Illinois
- Research Facility - Chicago
Other
- Research Facility - Randwick
Quebec
- Research Facility - Québec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 549 participants |
| Start Date | 2002-06 |
| Est. Completion | 2003-10 |
| Phase | Phase 3 |
What the finished NCT00349791 record still lists
NCT00349791 is an interventional study that assigns participants to a tested intervention. The registered 549 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Hypoactive Sexual Desire Disorder (HSDD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo patch is the first listed.
NCT00349791 reports a single indexed study location in Illinois, Other, Quebec.
Frequently Asked Questions
What is clinical trial NCT00349791 about?
NCT00349791 is a clinical study titled "Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido". This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
What is the current status of trial NCT00349791?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 549 participants. The study started on 2002-06. Estimated completion is 2003-10.
What conditions does trial NCT00349791 study?
This clinical trial studies the following conditions: Hypoactive Sexual Desire Disorder (HSDD).
What interventions are being tested in trial NCT00349791?
The interventions under investigation include: Placebo patch (DRUG), Testosterone Transdermal System (DRUG).
Who is sponsoring clinical trial NCT00349791?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00349791 being conducted?
This trial has 3 study locations across Illinois, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00349791's enrollment target sits among peer trials
549 689th of 2000 higher than 1,312 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia